Unknown

Dataset Information

0

Evaluation of 99mTc-labeled PSMA-SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapse.


ABSTRACT: Using conventional imaging modalities, it is difficult to detect recurrent lesions in prostate cancer patients who have undergone biochemical relapse, especially in patients with low prostate-specific antigen (PSA) levels. We retrospectively reviewed the files of fifty patients with histopathologically confirmed prostate cancer who underwent 99mTc-labeled prostate-specific membrane antigen (PSMA) single-photon emission computed tomography (SPECT)/computed tomography (CT), magnetic resonance imaging (MRI), and bone scan within a 30-day period. PSMA-SPECT/CT indicated metastatic lesions in 39 patients and had a higher detection rate (78.0%) than bone scan (34.0%) or MRI (40.0%). The diagnostic efficiency of PSMA-SPECT/CT imaging for bone and lymph node metastases (50.0% and 42.0%) was better than bone scan (34.0% and 0.0%) or MRI (24.0% and 20.0%). PSMA-SPECT/CT provided a higher detection rate at serum PSA levels of ?1 ng ml-1, 1-4 ng ml-1, 4-10 ng ml-1, and >10 ng ml-1. No correlation was found between Gleason score, PSA level, and the tracer tumor/background ratio of metastatic lesions. With the aid of PSMA-SPECT/CT imaging, the therapeutic strategy was changed for 31 patients, and this may have enhanced their clinical outcome. In conclusion, PSMA-SPECT/CT imaging could detect more metastatic lesions and achieve a higher detection rate than conventional imaging modalities at different serum PSA levels in prostate cancer patients who had undergone biochemical relapse.

SUBMITTER: Su HC 

PROVIDER: S-EPMC5427779 | biostudies-literature | 2017 May-Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Evaluation of 99mTc-labeled PSMA-SPECT/CT imaging in prostate cancer patients who have undergone biochemical relapse.

Su Heng-Chuan HC   Zhu Yao Y   Ling Guo-Wen GW   Hu Si-Long SL   Xu Xiao-Ping XP   Dai Bo B   Ye Ding-Wei DW  

Asian journal of andrology 20170501 3


Using conventional imaging modalities, it is difficult to detect recurrent lesions in prostate cancer patients who have undergone biochemical relapse, especially in patients with low prostate-specific antigen (PSA) levels. We retrospectively reviewed the files of fifty patients with histopathologically confirmed prostate cancer who underwent 99mTc-labeled prostate-specific membrane antigen (PSMA) single-photon emission computed tomography (SPECT)/computed tomography (CT), magnetic resonance imag  ...[more]

Similar Datasets

| S-EPMC4015168 | biostudies-literature
| S-EPMC5985225 | biostudies-literature
| S-EPMC3993876 | biostudies-other
| S-EPMC6562935 | biostudies-literature
| S-EPMC3341619 | biostudies-literature
| S-EPMC6836862 | biostudies-literature
| S-EPMC3716783 | biostudies-other
| S-EPMC7912279 | biostudies-literature
| S-EPMC3785531 | biostudies-other
| S-EPMC6771040 | biostudies-literature